Merus (MRUS) News Today → Read this before you buy AI stocks (From InvestorPlace) (Ad) Free MRUS Stock Alerts $43.63 -0.28 (-0.64%) (As of 04:17 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 17 at 6:47 AM | marketbeat.com46,120 Shares in Merus (NASDAQ:MRUS) Acquired by Jump Financial LLCJump Financial LLC acquired a new stake in Merus (NASDAQ:MRUS - Free Report) in the 4th quarter, according to the company in its most recent filing with the SEC. The fund acquired 46,120 shares of the biotechnology company's stock, valued at approximately $1,268,000. Jump Financial LLC owned aboutMay 17 at 1:56 AM | americanbankingnews.comMerus (NASDAQ:MRUS) Given Consensus Recommendation of "Buy" by AnalystsMay 17 at 1:53 AM | marketbeat.comMerus (NASDAQ:MRUS) Receives Average Recommendation of "Buy" from AnalystsShares of Merus (NASDAQ:MRUS - Get Free Report) have earned a consensus recommendation of "Buy" from the eleven analysts that are covering the firm, Marketbeat.com reports. Eleven research analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts thaMay 15, 2024 | americanbankingnews.comMerus (NASDAQ:MRUS) Upgraded to Hold by StockNews.comMay 15, 2024 | americanbankingnews.comMerus (NASDAQ:MRUS) Rating Reiterated by Needham & Company LLCMay 15, 2024 | marketbeat.comMerus (NASDAQ:MRUS) Upgraded to "Hold" by StockNews.comStockNews.com raised Merus from a "sell" rating to a "hold" rating in a research report on Tuesday.May 13, 2024 | finanznachrichten.deMerus N.V.: Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDAMay 13, 2024 | markets.businessinsider.comMerus Says FDA Grants Breakthrough Therapy Designation For Petosemtamab To Treat Head & Neck CancerMay 13, 2024 | markets.businessinsider.comBuy Rating on Merus Stock Amid Anticipation of Positive Clinical Trial Results and Growing Investor InterestMay 13, 2024 | msn.comMerus gets FDA breakthrough therapy status for petosemtamabMay 13, 2024 | marketbeat.comMerus (NASDAQ:MRUS) Earns "Buy" Rating from Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and issued a $66.00 price objective on shares of Merus in a research note on Monday.May 13, 2024 | globenewswire.comPetosemtamab granted Breakthrough Therapy Designation by the U.S. FDAMay 13, 2024 | americanbankingnews.comMerus' (MRUS) "Buy" Rating Reaffirmed at HC WainwrightMay 13, 2024 | americanbankingnews.comLeerink Partnrs Equities Analysts Increase Earnings Estimates for Merus (NASDAQ:MRUS)May 11, 2024 | finance.yahoo.comMerus N.V. (NASDAQ:MRUS) Just Reported First-Quarter Earnings And Analysts Are Lifting Their EstimatesMay 10, 2024 | finance.yahoo.comInvestors push Merus (NASDAQ:MRUS) 5.0% lower this week, company's increasing losses might be to blameMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed on Merus’s Clinical and Financial ProspectsMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Merus on Promising HNSCC Clinical Data and Competitive OutlookMay 9, 2024 | marketbeat.comMerus' (MRUS) Buy Rating Reaffirmed at HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $65.00 price target on shares of Merus in a research note on Thursday.May 9, 2024 | investorplace.comMRUS Stock Earnings: Merus Beats EPS, Misses Revenue for Q1 2024May 8, 2024 | finanznachrichten.deMerus N.V.: Merus Announces Financial Results for the First Quarter 2024 and Provides Business UpdateMay 8, 2024 | globenewswire.comMerus Announces Financial Results for the First Quarter 2024 and Provides Business UpdateMay 6, 2024 | msn.comFDA accepts Merus application for Zeno for lung, pancreatic cancerMay 6, 2024 | globenewswire.comMerus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDACApril 26, 2024 | seekingalpha.comMRUS Merus N.V.April 25, 2024 | marketbeat.comMerus (NASDAQ:MRUS) Shares Up 5.1%Merus (NASDAQ:MRUS) Trading Up 5.1%April 25, 2024 | finance.yahoo.comWill Merus N.V. (MRUS) Report Negative Q1 Earnings? What You Should KnowApril 24, 2024 | nasdaq.comValidea Detailed Fundamental Analysis - MRUSApril 24, 2024 | globenewswire.comMerus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual MeetingApril 22, 2024 | marketbeat.comMerus (NASDAQ:MRUS) Earns Outperform Rating from William BlairWilliam Blair restated an "outperform" rating on shares of Merus in a report on Monday.April 19, 2024 | marketbeat.comFederated Hermes Inc. Acquires 751,609 Shares of Merus (NASDAQ:MRUS)Federated Hermes Inc. grew its position in Merus (NASDAQ:MRUS - Free Report) by 26.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,637,309 shares of the biotechnology company's stock after acquiring an additional 7April 16, 2024 | marketbeat.com24,325 Shares in Merus (NASDAQ:MRUS) Acquired by HealthInvest Partners ABHealthInvest Partners AB purchased a new stake in Merus (NASDAQ:MRUS - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 24,325 shares of the biotechnology company's stock, valued at apprApril 15, 2024 | marketbeat.comMerus (NASDAQ:MRUS) Shares Purchased by DekaBank Deutsche GirozentraleDekaBank Deutsche Girozentrale increased its stake in shares of Merus (NASDAQ:MRUS - Free Report) by 124.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 56,000 shares of the biotechnology company's sApril 11, 2024 | marketbeat.comNeedham & Company LLC Reaffirms Buy Rating for Merus (NASDAQ:MRUS)Needham & Company LLC restated a "buy" rating and set a $66.00 price objective on shares of Merus in a research report on Thursday.April 10, 2024 | investing.comMerus reports progress on cancer therapy at AACR meetingApril 8, 2024 | finanznachrichten.deMerus N.V.: Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024April 8, 2024 | globenewswire.comMerus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024April 4, 2024 | marketbeat.comMerus (NASDAQ:MRUS) Shares Gap Up to $44.58Merus (NASDAQ:MRUS) Shares Gap Up to $44.58April 3, 2024 | finance.yahoo.comMerus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare ConferenceMarch 28, 2024 | marketbeat.comMerus (NASDAQ:MRUS) Earns Buy Rating from Analysts at Truist FinancialTruist Financial started coverage on Merus in a report on Thursday. They issued a "buy" rating and a $69.00 price target on the stock.March 25, 2024 | marketbeat.comMerus (NASDAQ:MRUS) Shares Down 4% Merus (NASDAQ:MRUS) Stock Price Down 4%March 19, 2024 | marketbeat.comMerus (NASDAQ:MRUS) Shares Bought by Wellington Management Group LLPWellington Management Group LLP boosted its position in shares of Merus (NASDAQ:MRUS - Free Report) by 2.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,735,247 shares of the biotechnoloMarch 15, 2024 | marketbeat.comHudson Bay Capital Management LP Boosts Stake in Merus (NASDAQ:MRUS)Hudson Bay Capital Management LP increased its holdings in Merus (NASDAQ:MRUS - Free Report) by 106.4% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 167,818 shares of the biotechnology company's stock after purchasing an additional 86,512 shares dMarch 12, 2024 | marketbeat.comMerus (NASDAQ:MRUS) Shares Down 5.2% Merus (NASDAQ:MRUS) Shares Down 5.2%March 12, 2024 | marketbeat.comMerus (NASDAQ:MRUS) Shares Bought by Carmignac GestionCarmignac Gestion increased its stake in Merus (NASDAQ:MRUS - Free Report) by 9.7% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 454,331 shares of the biotechnology company's stock after acquirinMarch 11, 2024 | finance.yahoo.comMRUS Dec 2024 50.000 callMarch 10, 2024 | finance.yahoo.comMRUS Jan 2025 50.000 putMarch 9, 2024 | finance.yahoo.comMRUS Apr 2024 35.000 putMarch 9, 2024 | finance.yahoo.comMRUS Apr 2024 40.000 callMarch 6, 2024 | marketwatch.comGilead, Merus to Collaborate on Trispecific Antibody Research Get Merus News Delivered to You Automatically Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Read this before you buy AI stocks (Ad)BREAKING: New "Formula" Could Lead to Huge AI Payouts When you click here and see what Elon Musk's new invention does… Investors — including multiple billionaires — are now tapping into a unique AI secret to pocket huge, consistent payouts. Starting today, you could siphon a new stream of income from this $3 billion pool of cash. MRUS Media Mentions By Week MRUS Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MRUS News Sentiment▼0.600.42▲Average Medical News Sentiment MRUS News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MRUS Articles This Week▼123▲MRUS Articles Average Week Get Merus News Delivered to You Automatically Sign up to receive the latest news and ratings for MRUS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ACADIA Pharmaceuticals News Today MoonLake Immunotherapeutics News Today Bausch Health Companies News Today MorphoSys News Today TG Therapeutics News Today Amicus Therapeutics News Today Arrowhead Pharmaceuticals News Today Corcept Therapeutics News Today Janux Therapeutics News Today IDEAYA Biosciences News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MRUS) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss RatingsShocking $16T Elon Musk Crypto LeakCrypto 101 Media"The Biggest Drug Ever" Is ComingBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersWarren Buffett's "mystery stock"Stansberry ResearchDigitizing the $11T commodities sector with one tiny stockResource Stock DigestElon to Transform U.S. Economy? Porter & Company Former CIA advisor: Dark side of AI now startingParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Merus Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
